دورية أكاديمية
In Sequence Anti-Fibrotic Treatment and Rehabilitation following Volumetric Muscle Loss Injury.
| العنوان: | In Sequence Anti-Fibrotic Treatment and Rehabilitation following Volumetric Muscle Loss Injury. |
|---|---|
| المؤلفون: | Nicholson PR; University of Minnesota, School of Kinesiology, Minneapolis, Minnesota, United States; nicho734@umn.edu., Raymond-Pope CJ; University of Minnesota, School of Kinesiology, Minneapolis, Minnesota, United States; raymo191@umn.edu., Lillquist TJ; University of Minnesota, School of Kinesiology, Minneapolis, Minnesota, United States; lillq014@umn.edu., Bruzina AS; University of Minnesota, School of Kinesiology, Minneapolis, Minnesota, United States; bruzi001@umn.edu., Call J; University of Georgia Department of Physiology & Pharmacology, 501 DW Brooks Dr, 3519 CVM, Athens, Georgia, United States, 30602; call@uga.edu., Greising SM; University of Minnesota, School of Kinesiology, 1900 University Ave SE, Minneapolis, Minneapolis, Minnesota, United States, 55455; grei0064@umn.edu. |
| المصدر: | Advances in wound care [Adv Wound Care (New Rochelle)] 2024 Aug 09. Date of Electronic Publication: 2024 Aug 09. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 101590593 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2162-1918 (Print) Linking ISSN: 21621918 NLM ISO Abbreviation: Adv Wound Care (New Rochelle) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New Rochelle, N.Y. : Mary Ann Liebert, Inc. |
| مستخلص: | Objective: Mitigation of local pathologic fibrotic tissue deposition is a target area of interest for volumetric muscle loss (VML); nintedanib has shown promise for reduction of fibrosis following VML. Herein studies investigate how in sequence anti-fibrotic treatment administered immediately following VML and delayed rehabilitation could improve functional recovery after VML. Approach: Adult male C57BL/6 mice (n=36) were VML injured or Naïve, and randomly assigned to nintedanib (6 mg/kg/day) for 2 weeks or were left untreated; additionally, mice were given access to a running wheel beginning at 2 weeks until 8 weeks. Terminally, mice underwent maximal in vivo functional testing in addition to quantification of muscle collagen content and fibrotic and myogenic markers. Results: Daily running distances (p=0.17) were similar across groups, but weekly averages were greatest in the VML anti-fibrotic group (p<0.01). As expected, 2 weeks post-VML, all VML-injured mice had lower maximal torque normalized to body and muscle mass than Naïve. By 8 weeks, running alone after VML did not recover function, but mice that received the anti-fibrotic treatment prior to running, had greater torque than those untreated (p<0.01), with functional measurements similar to naïve muscle thar ran, indicating improved functional recovery. Innovation: The ability to translate current FDA-approved pharmaceuticals, in a repurposing approach, is critical to mitigate the pathophysiologic consequences of VML in support of functional recovery. However, foundational and translational studies are still needed to understand feasibility and efficacy. Conclusions: Early prevention of fibrotic tissue deposition supports improvements in muscle quality and force chronically after VML injury. |
| معلومات مُعتمدة: | K02 AG081488 United States AG NIA NIH HHS; R01 AR078903 United States AR NIAMS NIH HHS |
| تواريخ الأحداث: | Date Created: 20240809 Latest Revision: 20240813 |
| رمز التحديث: | 20240813 |
| DOI: | 10.1089/wound.2024.0109 |
| PMID: | 39119810 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!